OCT Angiographic Findings in Retinal Angiomatous Proliferation

Abstract

Background OCT angiography (OCT-A) allows non-invasive blood flow registration of the retina and choroid. In contrast to fluorescein angiography (FA), no dye has to be administered. The OCT-A also provides depth-selective information. OCT-A and FA were compared in patients with neovascular age-related macular degeneration (AMD) with retinal angiomatous proliferation (RAP) stage 1. In stage 1, the neovascularizations are intraretinal. In contrast to the two-dimensional total image of the FA, the OCT-A allows a depth-selective display of the individual retinal layers. In this way, a conclusion can be drawn about the place of origin of the RAP.

Patients and Methods Three patients with neovascular AMD and RAP stage 1 were included. They were examined with OCT (ZEISS CIRRUS HD-OCT 5000, Carl Zeiss Meditec, Inc., Dublin, USA), OCT-A (ZEISS AngioPlex OCT-Angiography) as well as FA (HRA2, Heidelberg Engineering) between January 2016 and March 2019. A complete ophthalmological examination was performed. A qualitative analysis of the OCT-A images (3 × 3 and 6 × 6 mm) and the FA images was carried out. Leaks in the FA were compared with the en-face images of the OCT-A followed by a depth-selective assignment using the corresponding B-scans of the OCT-A.

Results It was one woman and two men aged 66 – 89 years. The visual acuity was 0.4 in the first, 0.5 p in the second and 0.8 in the third patient. The diagnosis of RAP stage 1 could be made both in the OCT, the FA and the OCT-A. All patients showed macular edema in the OCT. The FA showed selective hyperfluorescence in the early phase and fluorescein extravasation in the late phase. In OCT-A, the blood flow in all patients could be shown in the hyperreflective structure of the RAP in the B-scan. The first patient showed two RAP lesions in the FA, which were in the deep vascular plexus in the OCT-A. In the second patient, three RAP lesions were found in the FA, and a total of five RAP lesions in the OCT-A. One could be located in the superficial and deep vascular plexus, four in the deep vascular plexus. The third patient showed one RAP lesion in the FA as well as in the OCT-A, which could be assigned to the superficial vascular plexus.

Conclusion The OCT-A is well suited for the diagnosis of RAP stage 1. In the present cases, the diagnosis in the OCT-A could be made as clearly as by FA. A major advantage of the OCT-A results from the non-invasive character and the depth selectivity. The RAP 1 lesions could be assigned to both the superficial and the deep vascular plexus. Depth selection is not possible with the FA due to the summary picture.

Key words

retinal angiomatous proliferation - neovascular age-related macular degeneration - OCT-angiography

Publication History

Received: 26 March 2020

Accepted: 09 July 2020

Article published online:
31 August 2020

• References/Literatur

• 1 Dansingani KK, Naysan J, Freund KB. En face OCT angiography demonstrates flow in early type 3 neovascularization (retinal angiomatous proliferation). Eye (Lond) 2015; 29: 703-706 doi:10.1038/eye.2015.27
• 2 Politoa A, Napolitano MC, Bandello F. et al. The role of optical coherence tomography (OCT) in the diagnosis and management of retinal angiomatous proliferation (RAP) in patients with age-related macular degeneration. Ann Acad Med Singapore 2006; 35: 420-424
• 3 de Jong JH, Braaf B, Amarakoon S. et al. Treatment effects in retinal angiomatous proliferation imaged with OCT angiography. Ophthalmologica 2019; 241: 143-153 doi:10.1159/000491798
• 4 Sandner D. [Choroidal neovascularisation other than typical neovascular age-related macular degeneration]. Klin Monbl Augenheilkd 2018; 235: 905-926 doi:10.1055/s-0042-123833
• 5 Kuerzinger GR, Lang GK, Lang GE. [Retinal angiomatous proliferation in age-related macular degeneration]. Klin Monbl Augenheilkd 2006; 223: 691-695 doi:10.1055/s-2006-926977
• 6 Stoffelns BM, Kramann C, Schoepfer K. [Laser photocoagulation and photodynamic therapy (PDT) with verteporfin for retinal angiomatous proliferation (RAP) in age-related macular degeneration (AMD)]. Klin Monbl Augenheilkd 2008; 225: 392-396 doi:10.1055/s-2008-1027251
• 7 Malamos P, Tservakis I, Kanakis M. et al. Long-term results of combination treatment with single-dose ranibizumab plus photodynamic therapy for retinal angiomatous proliferation. Ophthalmologica 2018; 240: 213-221 doi:10.1159/000487610
• 8 Arias L, Gómez-Ulla F, Ruiz-Moreno JM. Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation. Clin Ophthalmol 2016; 10: 861-869 doi:10.2147/OPTH.S106092
• 9 Browning AC, OʼBrien JM, Vieira RV. et al. Intravitreal aflibercept for retinal angiomatous proliferation: results of a prospective case series at 96 weeks. Ophthalmologica 2019; 242: 239-246 doi:10.1159/000500203
• 10 Rezar-Dreindl S, Eibenberger K, Buehl W. et al. Clinical outcomes of different subtypes of neovascular age-related macular degeneration during aflibercept treatment. Retina 2020; DOI: 10.1097/IAE.0000000000002786.
• 11 Daniel E, Shaffer J, Ying G-S. et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology 2016; 123: 609-616 doi:10.1016/j.ophtha.2015.10.034
• 12 Yannuzzi LA, Negrão S, Iida T. et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21: 416-434 doi:10.1097/00006982-200110000-00003
• 13 Lang GE, Enders C, Werner JU. [New possibilities in retinal diagnostics using OCT angiography]. Klin Monbl Augenheilkd 2016; 233: 613-621 doi:10.1055/s-0042-105325
• 14 Berufsverband der Augenärzte Deutschlands, Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft. Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft. OCT-Angiographie in Deutschland: Präsentation, Nomenklatur und Zukunftswünsche. Stand Januar 2017. Im Internet (Stand: 02.01.2020): https://www.dog.org/wp-content/uploads/2017/05/Stellungnahme-_OCT-Angiographie.pdf
• 15 Enders C, Baeurle F, Lang GE. et al. [Visualization of retinal neovascularization with optical coherence tomography in comparison with fluorescein angiography]. Klin Monbl Augenheilkd 2019; 236: 1325-1330 doi:10.1055/a-0983-2271
• 16 Enders C, Lang GE, Dreyhaupt J. et al. Quantity and quality of image artifacts in optical coherence tomography angiography. PLoS One 2019; 14: e0210505 doi:10.1371/journal.pone.0210505
• 17 Querques G, Rousseau A, Forte R. et al. Longitudinal anatomical response of retinal-choroidal anastomosis to anti-vascular endothelial growth factor therapy. Retina 2012; 32: 458-467 doi:10.1097/IAE.0b013e3182205960
• 18 Maruyama-Inoue M, Sato S, Yamane S. et al. Predictive factors and long-term visual outcomes after anti-vascular endothelial growth factor treatment of retinal angiomatous proliferation. Clin Ophthalmol 2019; 13: 1981-1989 doi:10.2147/OPTH.S224319
• 19 Kim JH, Kim JW, Kim CG. et al. Long-term treatment outcomes in type 3 neovascularization: focus on the difference in outcomes between geographic atrophy and fibrotic scarring. J Clin Med 2020; DOI: 10.3390/jcm9041145.
• 20 de Jong JH, Braaf B, Amarakoon S. et al. Treatment effects in retinal angiomatous proliferation imaged with OCT angiography. Ophthalmologica 2019; 241: 143-153 doi:10.1159/000491798
• 21 Borrelli E, Souied EH, Freund KB. et al. Reduced choriocapillaris flow in eyes with type 3 neovascularization and age-related macular degeneration. Retina 2018; 38: 1968-1976 doi:10.1097/IAE.0000000000002198
• 22 Kim JH, Kim JR, Kang SW. et al. Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. Am J Ophthalmol 2013; 155: 743-749 doi:10.1016/j.ajo.2012.11.001
• 23 Yamazaki T, Koizumi H, Yamagishi T. et al. Subfoveal choroidal thickness in retinal angiomatous proliferation. Retina 2014; 34: 1316-1322 doi:10.1097/IAE.0000000000000086
• 24 Querques G, Kuhn D, Massamba N. et al. Perifoveal exudative vascular anomalous complex. J Fr Ophtalmol 2011; 34: 559.e1-e4 doi:10.1016/j.jfo.2011.03.002
• 25 Sacconi R, Freund KB, Yannuzzi LA. et al. The expanded spectrum of perifoveal exudative vascular anomalous complex. Am J Ophthalmol 2017; 184: 137-146 doi:10.1016/j.ajo.2017.10.009
• 26 Sacconi R, Borrelli E, Sadda S. et al. Non-exudative perifoveal vascular anomalous complex: the sub-clinical stage of perifoveal exudative vascular anomalous complex?. Am J Ophthalmol 2020; DOI: 10.1016/j.ajo.2020.04.025.
• 27 Mrejen S, Le HM, Nghiem-Buffet S. et al. Insights into perifoveal exudative vascular anomalous complex. Retina 2020; 40: 80-86 doi:10.1097/IAE.0000000000002435
• 28 Mao J, Cheng D, Lin J. et al. Evaluating retinal angiomatous proliferation with optical coherence tomography angiography. Ophthalmic Surg Lasers Imaging Retina 2020; 51: 136-144 doi:10.3928/23258160-20200228-02